Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (591)	3/10/2005 4:33:56 PM
From: Rudy Saucillo	of 946

>>I'm not sure how common that doublet is now.<< From the literature it appears that paclitaxel and cisplatin (a platinum) is a fairly common doublet in front-line NSCLC, especially with brain mets. I can understand why front-line patients treated with docetaxel were excluded (for the same reasons that any patients previously treated with PEG paclitaxel were excluded). It wouldn't be ethical to randomize a patient who previously failed docetaxel to a docetaxel arm (and the FDA wouldn't see that patient as a representative comparator to patients in the PEG paclitaxel arm). That certainly increases the hurdle for Xyo, IMO. Let's hope the SPA revision to include non-inferiority as a primary endpoint is approved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next